ORIC Pharmaceuticals Stock
ORIC Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jacob Chacko
- Employees
- 111
- Market cap
- $1.3 B
- IPO
- 24/04/2020
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company was founded in 2014 and maintains its headquarters in South San Francisco, California. Its pipeline includes several key…
Company description based on the data provider's company data, AI-assisted, created on 17/10/2026. Not investment advice.
ORIC Pharmaceuticals stock: price history
1D
-3.3%
1W
+3.0%
1M
-1.5%
6M
+14.9%
YTD
+51.0%
1Y
-7.1%
2Y
+28.0%
5Y
-23.9%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~11% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about ORIC Pharmaceuticals
Analyst assessment of ORIC Pharmaceuticals
PRICE TARGET LOW
US$15.00
CONSENSUS
US$23.50
MEDIAN
US$26.00
PRICE TARGET HIGH
US$27.00
0
STRONG BUY
10
BUY
0
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 14/10/2026
ORIC Pharmaceuticals stock metrics
P/E
-9.15
P/B
3.5
EV/EBITDA
-8.71
RETURN ON EQUITY
-10.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
47.1%
FLOAT SHARES
48,769,922
AVG. DAILY VOLUME (30D)
1,509,455
Insider transactions (SEC)
Heyman Richard A.
Heyman Richard A.
Heyman Richard A.
Piscitelli Dominic
Piscitelli Dominic
Institutional holders
Comparable stocks
Frequently asked questions about ORIC Pharmaceuticals stock
What does ORIC Pharmaceuticals do?
ORIC Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jacob Chacko, the company employs around 111 people.
The IPO was on 24/04/2020; the stock trades on NASDAQ under the ticker ORIC.
What do analysts say about ORIC Pharmaceuticals stock?
10 analysts rate the stock, the consensus is Buy (as of 14/10/2026).
The average price target is US$23.50, ranging from US$15.00 to US$27.00, with a median of US$26.00.
This is an external assessment, not a statement by Market Jury.
When does ORIC Pharmaceuticals report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 11% stronger than usual.
Does ORIC Pharmaceuticals pay a dividend?
No, ORIC Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to ORIC Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get ORIC Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess ORIC Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.